 |
|
|
| |
Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers
|
| |
| |
Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections, March 3Ð6, 2013
John P Sabo,1 Jens Kort,1 Manuel Haschke,2
Charles Ballow,3 Birgit Girlich,4 Ulrich Feifel,5
Benjamin Lang,6 Michael Schobelock,1 Mabrouk Elgadi7
1Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA; 2University Hospital Basel, Basel, Switzerland; 3Buffalo Clinical Research Center, Buffalo, NY, USA; 4Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 5Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Ingelheim, Germany;
6Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Biberach, Germany;
7Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario, Canada
|
| |
|
|
|
|
|
